Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer
Datroway is approved in the US as the first TROP2-directed antibody drug conjugate for 1st-line treatment of metastatic triple-negative breast cancer.
Asset / Drug
Drug and asset intelligence for Datroway with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.